Skip to Content
 

VICC toll-free number 1-877-936-8422

Clinical Trials for Letrozole

5 Open Trials

    Trial Type Protocol No. &
    Open Date
    Summary

    Treatment

    VICCBRE1804

    05/01/2018

    Phase 1b Study to Assess the Safety, Tolerability, and Clinical Activity of Gedatolisib in Combination with Palbociclib and Either Letrozole or Fulvestrant in Women with Metastatic or Locally Advanced/Recurrent Breast Cancer (MBC)

    Treatment

    VICCBRE1732

    04/04/2018

    PELOPS: Palbociclib and Endocrine Therapy for Lobular Breast Cancer Preoperative Study: A Randomized Phase II Study of Palbociclib with Endocrine Therapy versus Endocrine Therapy Alone for Invasive Lobular Carcinoma and Invasive Ductal Carcinoma

    Treatment

    VICCBRE15147

    01/20/2017

    A randoMized phAse II trIal of fulvestraNt wiTh or without Ribociclib After progression on AntI-estrogeN therapy plus cyclin-dependent kinase 4/6 inhibition in patients with unresectable or metastatic hormone receptor positive, HER2 negative breast cancer (MAINTAIN Trial)

    Treatment

    VICCBRE1640

    11/10/2016

    PALLAS: Palbociclib Collaborative Adjuvant Study: A Randomized Phase III Trial of Palbociclib with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone for Hormone Receptor Positive (HR+) / Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Early Breast Cancer

    Treatment

    ECOGBRES1207

    10/31/2013

    Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer. e3 Breast Cancer Study- evaluating everolimus with endocrine therapy.


    Print this page for your doctor